M94. Genetic Analyses of Cognitive Performance in Psychotic Disorders from the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP) Consortium
Jeffrey Bishop,Scot Hill,Lauren Mills,Ney Alliey-Rodriguez,James Reilly,Rebecca Shaffee,Steve McCarroll,Richard Keefe,Godfrey Pearlson,Brett Clementz,Carol Tamminga,Matcheri Keshavan,Elliot Gershon,John Sweeney
DOI: https://doi.org/10.1093/schbul/sbx022.089
2017-01-01
Schizophrenia Bulletin
Abstract:Background: Cognitive deficits are present and familial in psychotic disorders and understanding the genetic contributors to these impairments in patients as well as healthy controls can contribute to our understanding of disease pathophysiology and its behavioral consequences. Methods: The Brief Assessment of Cognition in Schizophrenia (BACS) was administered to 1059 participants (schizophrenia N = 299, schizoaffective disorder N = 179, psychotic bipolar disorder N = 236, and controls N = 345). Participants were 15–65 years of age, clinically stable outpatients, and without significant neurological disorder, recent substance abuse, or dependence. Genotyping was performed using the Illumina PsychChip followed by imputation using the 1000 Genomes reference panel resulting in ~4.3 million SNP markers. The primary analysis was a mixed modeling GWAS approach (EMMAX) performed using BACS composite Z scores examined as a quantitative trait phenotype while controlling for genetically-driven ancestry measures, age, and sex. A secondary analysis additionally controlled for COMT Val158Met (rs4680) allele dosage which is a significant driver of cortical dopamine (DA) disposition. Probands and controls were grouped together and then also stratified by the top 2 genetically-derived ancestry groups. Results: The most prominent region associated with BACS performance across all participants was the SFMBT1 locus on Chr3 (lowest P = 1.110E-7; N = 18 SNPs P < 1.0E-5). Robust associations with the noncoding RNA LCO101928516 locus on chromosome 6 (lowest P = 4.1 × 10E-8; N = 14 SNPs P < 1 × 10E-5) were identified in participants of African ancestry. Additionally there were N = 30 genes or defined genetic loci harboring SNPs with suggestive (P < 1E-5) associations with BACS performance. Notable trends include genes previously associated with risk for schizophrenia or bipolar disorder (CDH12, DNM3, ITIH1, ITIH4, LRFN5, NMBR, NTRK3); brain structure, white matter, or development (INPP5D, LRFN5, NTRK3); and cognition (AKAP6, TNFSF10). After controlling for COMT Val158Met allele status, the microRNA gene (MIR44198b) on Chr12 revealed association trends (lowest P = 5.8 × 10E-8; N = 27 SNPs P < 1 × 10E-5) in those of African ancestry. Conclusion: The most prominent associations with performance across all participants were at the SFMBT1 locus related to histone and chromatin regulation. Other genes harboring suggestive findings include those previously associated with risk for psychotic disorders, brain structure or development, and cognition. When controlling for COMT Val158Met allele status, numerous SNPs in MIR44198b, which is known to target immunological regulators, revealed associations. These data suggest that cognitive impairments in psychotic disorders may be influenced by genes also known to be risk factors for psychiatric disorders, but also other genes related to brain processes, epigenetic gene regulation, or inflammation.